ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Wang, Jie; Zhou, Caicun; Yao, Wenxiu; Wang, Qiming; Min, Xuhong; Chen, Gongyan; Xu, Xingxiang; Li, Xingya; Xu, Fei; Fang, Yong; Yang, Runxiang; Yu, Guohua; Gong, Youling; Zhao, Jun; Fan, Yun; Liu, Quan; Cao, Lejie; Yao, Yu; Liu, Yunpeng; Li, Xiaoling; Wu, Jingxun; He, Zhiyong; Lu, Kaihua; Jiang, Liyan; Hu, Chengping; Zhao, Wenhua; Zhang, Ben; Shi, Wei; Zhang, Xiaojing; Cheng, Ying*南昌大学; 江南大学; 哈尔滨医科大学; 四川大学; 浙江大学; 郑州大学; 西安交通大学; 厦门大学; 中国医科大学; 中国医学科学院; 中国医学科学院北京协和医院; 1; y
LANCET ONCOLOGY2022-6DOI: 10.1016/S1470-2045(22)00224-8
90被引6阅读
引用收藏
分享

摘要

Background Extensive-stage small-cell lung cancer (ES-SCLC) is associated with poor prognosis and treatment options are scarce. Immunotherapy has shown robust clinical activity in ES-SCLC in previous phase 3 trials. We aimed to assess the efficacy and safety of adebrelimab (SHR-1316), a novel anti-PD-L1 antibody, with standard chemotherapy as a first-line treatment for ES-SCLC. Methods The CAPSTONE-1 study was a randomised, double-blind, placebo-controlled, phase 3 trial, done in 47 tertiary hospitals in China. Key inclusion criteria were patients aged 18-75 years, with previously untreated histologically or cytologically confirmed ES-SCLC and an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. Eligible patients were randomly assigned (1:1) to receive four to six cycles of carboplatin (area under the curve of 5 mg/mL per min, day 1 of each cycle) and etoposide (100 mg/m2 of body-surface area, on days 1-3 of each cycle) with either adebrelimab (20 mg/kg, day 1 of each cycle) or matching placebo, followed by maintenance therapy with adebrelimab or placebo. All treatments were given intravenously in 21-day cycles. Randomisation was done using a centralised interactive web response system with a block size of four, stratified by liver metastases, brain metastases, and lactate dehydrogenase concentration. The primary endpoint was overall survival in patients who received at least one dose of study medication. Safety was analysed in the as-treated population. This study is complete and registered with ClinicalTrials.gov, NCT03711305. Findings Between Dec 26, 2018, and Sept 4, 2020, 462 eligible patients were enrolled and randomly assigned: 230 (50%) patients received adebrelimab plus chemotherapy (adebrelimab group) and 232 (50%) patients received placebo plus chemotherapy (placebo group). At data cutoff (Oct 8, 2021), median follow-up was 13.5 months (IQR 8.9-20.1). Median overall survival was significantly improved in the adebrelimab group (median 15.3 months [95% CI 13.2-17.5]) compared with the placebo group (12.8 months [11.3-13.7]; hazard ratio 0.72 [95% CI 0.58-0.90]; one-sided p=0.0017). The most common treatment-related grade 3 or 4 adverse events were decreased neutrophil count (174 [76%] patients in the adebrelimab group and 175 [75%] patients in the placebo group), decreased white blood cell count (106 [46%] and 88 [38%]), decreased platelet count (88 [38%] and 78 [34%]), and anaemia (64 [28%] and 66 [28%]). Treatment-related serious adverse events occurred in 89 (39%) patients in the adebrelimab group and 66 (28%) patients in the placebo group. Four treatment-related deaths were reported: two each in the adebrelimab group (respiratory failure and interstitial lung disease and pneumonia) and placebo group (multiple organ dysfunction and unknown cause of death). Interpretation Adding adebrelimab to chemotherapy significantly improved overall survival with an acceptable safety profile in patients with ES-SCLC, supporting this combination as a new first-line treatment option for this population.

学科与关键词

关键词
PLATINUM
相关
加载中…
  • Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage SCLC: A phase 3 trial.
    Cheng, Ying; Wang, Jie; Zhou, Caicun; Yao, Wenxiu; Wang, Qiming; Min, Xuhong; Chen, Gongyan; Xu, Xingxiang; Li, Xingya; Xu, Fei; Fang, Yong; Yang, Runxiang; Yu, Guohua; Gong, Youling; Zhao, Jun; Fan, Yun; Liu, Quan; Cao, Lejie; Yao, Yu; Liu, Yunpeng; Li, Xiaoling; Wu, Jingxun; He, Zhiyong; Lu, Kaihua; Jiang, Liyan; Yu, Huiqing; Hu, Chengping; Zhao, Wenhua; Zhao, Jian; Wu, Gang; Huang, Dingzhi; Chen, Chengshui; Ding, Cuimin; Zhang, Baihong; Wang, Xiuwen; Luo, Hui; Li, Baolan; Zhang, BenAnnual Meeting of the American-Association-for-Cancer-Research (AACR), New Orleans, LA, 2022-04-08 To 2022-04-13.
  • Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer The ASTRUM-005 Randomized Clinical Trial
    Cheng, Ying*; Han, Liang; Wu, Lin; Chen, Jun; Sun, Hongmei; Wen, Guilan; Ji, Yinghua; Dvorkin, Mikhail; Shi, Jianhua; Pan, Zhijie; Shi, Jinsheng; Wang, Xicheng; Bai, Yuansong; Melkadze, Tamar; Pan, Yueyin; Min, Xuhong; Viguro, Maksym; Li, Xingya; Zhao, Yanqiu; Yang, Junquan; Makharadze, Tamta; Arkania, Ekaterine; Kang, Wenying; Wang, Qingyu; Zhu, JunJAMA, 2022, 328(12): 1223-1232.被引 88
  • Anti-PD-L1 immune checkpoint inhibitors in combination with etoposide and platinum for extensive-stage small cell lung cancer: a case report
    Xue, Lei; Chen, Baishen; Lin, Junshuang; Peng, Jiangzhou*Annals of Palliative Medicine, 2021, 10(1): 828-835.被引 2
查看全部 →

发表信息

论文状态
公开发表
期刊
LANCET ONCOLOGY
发表日期
2022-06
卷期
第 23 卷, 第 6 期
页码
739-747
DOI
10.1016/S1470-2045(22)00224-8
语言
ENGLISH
期刊等级
1区
成果收录
SCIE
资助标注
Jiangsu Hengrui Pharmaceuticals

作者

  • W

    Wang, Jie (第一作者)

    chinese acad med sci · peking union med coll

  • Z

    Zhou, Caicun

    shanghai pulm hosp

查看全部 30 位作者收起作者
  • Y

    Yao, Wenxiu

    sichuan canc hosp & inst

  • W

    Wang, Qiming

    zhengzhou univ

  • M

    Min, Xuhong

  • C

    Chen, Gongyan

    harbin med univ

  • X

    Xu, Xingxiang

  • L

    Li, Xingya

    1 · zhengzhou univ

  • X

    Xu, Fei

    1 · nanchang univ

  • F

    Fang, Yong

    zhejiang univ

  • Y

    Yang, Runxiang

  • Y

    Yu, Guohua

    weifang peoples hosp

  • G

    Gong, Youling

    sichuan univ

  • Z

    Zhao, Jun

  • F

    Fan, Yun

    zhejiang canc hosp

  • L

    Liu, Quan

    jiangnan univ

  • C

    Cao, Lejie

    anhui prov hosp · univ sci & technol china

  • Y

    Yao, Yu

    1 · xi an jiao tong univ

  • L

    Liu, Yunpeng

    china med univ

  • L

    Li, Xiaoling

    liaoning canc hosp & inst

  • W

    Wu, Jingxun

    1 · xiamen univ

  • H

    He, Zhiyong

    fujian canc hosp · fujian med univ

  • L

    Lu, Kaihua

  • J

    Jiang, Liyan

  • H

    Hu, Chengping

  • Z

    Zhao, Wenhua

    guangxi med univ

  • Z

    Zhang, Ben

  • S

    Shi, Wei

  • Z

    Zhang, Xiaojing

  • C

    Cheng, Ying (通讯)

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417